SWOG clinical trial number
CTSU/A081801

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Open
Abbreviated Title
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Status Notes
Effective immediately, October 22, 2021, A081801 will be temporarily closed to accrual.
Activated
06/23/2020

Research committees

Lung Cancer

Treatment

Cisplatin Carboplatin Gemcitabine hydrochloride Radiation Therapy Pemetrexed MK-3475 Paclitaxel

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2021

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

J Sands;S Mandrekar;D Kozono;G Oxnard;S Hillman;D Wigle;R Govindan;J Carlisle;J Gray;J Salama;L Raez;A Ganti;N Foster;S Malik;J Bradley;K Kelly;S Ramalingam;T Stinchcombe Immunotherapy Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21

PMid: PMID33878954 | PMC number: PMC8293026

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/NRG-LU007
SWOG Clinical Trial Number
CTSU/A081801